TERN News and Press, Terns Pharmaceuticals Inc. From 08/04/25

FOSTER CITY, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including o...

Kyndryl Holdings Inc. (KD) is expected to report $0.25 for Q1 2026 Bruker Corporation (BRKR) is expected to report $0.33 for Q2 2025 Vornado Realty Trust (VNO) is expected to report $0.53 for Q2 2025 Diamondback Energy Inc. (FANG) is expected to report $2.63 for Q2 2025 Freightcar...

Terns Pharmaceuticals Inc. (TERN) is expected to report $-0.28 for Q2 2025

2025-07-11 11:27:44 ET Terns Overview - Two Key Candidates With Data Catalysts In Q4, Funding Into 2028 Read the full article on Seeking Alpha For further details see: Terns Pharmaceuticals: A Risky Buy Ahead Of Q4 Obesity, Oncology Catalysts

Phase 1 clinical study of TERN-601 demonstrated differentiated profile in 28-day study; topline data were presented in September 2024 Phase 2 FALCON clinical trial of TERN-601 completed enrollment; 12-week data expected in 4Q 2025 FOSTER CITY, Calif., June 23, 2025 (GLOBE NEWSWIRE) ...

2025-05-16 16:24:43 ET Summary Zealand Pharma A/S is a leading non-Big Pharma player in obesity drugs, with a promising pipeline and a major partnership with Roche for petrelintide. Petrelintide, an amylin analog, could rival current market leaders if clinical data proves best-in-...

Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations Early dose-escalation data from Phase 1 CARDINAL study of TERN-701 in CML patients showed compelling molecular responses in p...

Redwire Corporation (RDW) is expected to report $-0.2 for Q1 2025 Organigram Global Inc. (OGI) is expected to report $-0.03 for Q2 2025 Inter & Co. Inc. (INTR) is expected to report $0.12 for Q1 2025 Pervasip Corp (PVSP) is expected to report for quarter end 2025-02-28 Maui La...

2025-05-11 18:48:13 ET Terns Pharmaceuticals, Inc. (TERN) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 4.92%. The average open to low on the day of earnings was -3.74%. The average op...

2025-05-11 18:43:14 ET Terns Pharmaceuticals, Inc. (TERN) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in TERN stock price following earnings has averaged ±2.84% , with a median of 1.7...